1. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center
   Anuj K. Patel et al, 2021, The Oncologist CrossRef
2. Meta-Analysis of Regorafenib-Associated Adverse Events and Their Management in Colorectal and Gastrointestinal Stromal Cancers
   Ganfeng Xie et al, 2019, Advances in Therapy CrossRef
3. Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms
   Akimitsu Maeda et al, 2019, Cancer Chemotherapy and Pharmacology CrossRef
4. Impact of sarcopenia in patients with advanced or recurrent colorectal cancer treated with regorafenib
   Yasushi Murachi et al, 2021, International Journal of Clinical Oncology CrossRef
5. A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
   Wu-Song Xue et al, 2018, Medicine CrossRef
6. Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice
   Tanios Bekaii-Saab et al, 2019, Clinical Colorectal Cancer CrossRef
7. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial
   Cheng-Jen Ma et al, 2019, Trials CrossRef
8. Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study
   Masayuki Nakashima et al, 2023, BMC Cancer CrossRef
9. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review
   Maria Røed Skårderud et al, 2018, Cancer Treatment Reviews CrossRef
10. Therapeutic Potential of Regorafenib in Cisplatin-Resistant Bladder Cancer with High Epithelial–Mesenchymal Transition and Stemness Properties
    Feng-Che Kuan et al, 2023, International Journal of Molecular Sciences CrossRef
11. Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third‑line or later chemotherapy regimen for refractory metastatic colorectal cancer
    Akira Tanaka et al, 2018, Oncology Letters CrossRef
12. Practical considerations in the use of regorafenib in metastatic colorectal cancer
    Fotios Loupakis et al, 2020, Therapeutic Advances in Medical Oncology CrossRef
13. Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib
    Bin Zhao et al, 2017, Oncotarget CrossRef
14. Incidence and risk of regorafenib-induced hepatotoxicity
    Bin Zhao et al, 2017, Oncotarget CrossRef
15. Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting
    Cheng-Jen Ma et al, 2019, Translational Oncology CrossRef
16. Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study
    Masayuki Nakashima et al, 2019, Targeted Oncology CrossRef